RxDoctor Payments Data

Kayven Farshad, MD

Pain Medicine · Tucson, AZNPI 1841678307

Payments from drug & device makers

What this record shows

The money is spread across several categories — grants (46.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by Boston Scientific at 52.6% of the total. Reporting peaked in 2019 at $15,414 and has fallen 89.0% since, to $1,691 in 2025. Among pain medicine clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$27,470in general payments, 2019–2025

Across 413 payments — averaging $66.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$14K
  • Nalu Medical, Inc.$3K
  • Abbott$2K
  • Medtronic$2K
  • Stryker$1K
  • Nevro Corp.$892
  • plus $4K from 27 others

What the payments were for

  • Grants$12,82147%
  • Travel & lodging$3,81714%
  • Food & beverage$10,83339%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,470 in reported general payments places this provider in the 90th percentile of 180 pain medicine providers in Arizona.

See all pain medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$320,930
Medicare patients
692
Services billed
5,589

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate12$5,458
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen217$4,391
Naloxone Hcl57$3,350
Oxycodone Hcl160$2,184
Pregabalin66$2,027
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen74$1,977
Gabapentin148$1,782
Morphine Sulfate ErMorphine Sulfate37$1,078
Lidocaine11$674
Tramadol Hcl73$639
Tizanidine Hcl44$498
Duloxetine Hcl17$474
Morphine Sulfate14$405
Methocarbamol19$264
Baclofen16$186

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$886$5,45812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 180 pain medicine providers in Arizona.

Other pain medicine in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →